---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-048042"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2021-09-15T23:59:59+00:00"
generated_at: "2026-06-29T03:34:36.320653+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AbCellera acquires TetraGenetics for $12.5M upfront to boost antibody discovery

## Summary
- Upfront cash consideration of $12.5M; additional technical, development, and commercial milestones possible.
- TetraGenetics specializes in recombinant ion channels, GPCRs, and other transmembrane proteins.
- Acquisition integrates TetraGenetics' protein expression platform into AbCellera's antibody discovery stack.
- Deal aims to unlock antibody therapies against difficult-to-drug transmembrane targets.

## SEC filing metadata
- accession: 0001564590-21-048042
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2021-09-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000156459021048042/0001564590-21-048042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000156459021048042/abcl-8k_20210913.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-048042
- JSON: https://secwatch.observer/filing/0001564590-21-048042.json
- Plain text: https://secwatch.observer/filing/0001564590-21-048042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.